🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the pathogen, according to scientists.

A Global Public Health Issue

Cases of gonorrhoea are escalating globally, with figures suggesting in excess of 82 million infections each year. Especially elevated rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary advancement in the reality of rising global incidence, the spread of superbugs and the extremely scarce treatment choices at this time.”

Medical experts are deeply concerned about the rise in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Secure Authorization

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the American regulatory agency in mid-December for combating gonorrhoea. This STI can lead to major issues, including infertility. Experts believe that targeted use of this new drug will help delay the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This drug, which is also used to treat urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to develop it.

“This authorization represents a significant shift in the treatment of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Research Study Outcomes and Global Access

According to data released by a prominent scientific publication, zoliflodacin cured the vast majority of genital gonorrhoea infections. This places it at an equal footing with the typical regimen, which combines two antibiotics. The research included nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals treating patients have expressed hope. Access to a single-dose, oral treatment of this kind is seen as a "game-changer" for public health efforts. This is considered essential to alleviate the strain of the illness for people and to prevent the spread of untreatable gonorrhoea around the world.